Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|16|2|303-315

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.16, Iss.2, 2018-02, pp. : 303-315

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 766-771

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 300-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Gringeri et al.: ‘recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling’

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : e489-e492

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparison

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 219-226

John Wiley & Sons Inc

Access to resources Recommend Favorite